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While watching the news on TV at the end of March this 
year, did you notice snapshots from Chicago where one 
of the largest convention centers — McCormick Place 
Convention Center — was turned into an isolation facility 
with hundreds of beds for COVID-19 (coronavirus disease 
2019) infected patients? This was the very facility that was 
supposed to host the American College of Cardiology’s 
69th Annual Scientific Session & Expo and the World Heart 
Federation Congress. The pandemic did not prevent the 
organizers of this prestigious meeting from presenting 
to would-be visitors to the “Windy City” the latest results 
of clinical trials, attractive didactic sessions, enabling 
participation in poster sessions, and even a virtual walk 
through the exhibition of pharmaceutical and equipment 
companies. The whole of this year’s congress took place 
for the first time ever online. We present a selection of 
the latest clinical trials that we believe deserve to be 
popularized.
The results of the VICTORIA (A study of vericiguat in 
participants with heart failure with reduced ejection frac-
tion) program on the evaluation of the role of vericiguat in 
patients with heart failure with reduced ejection fraction 
(HFrEF) were presented by its principal investigator, Dr. Paul 
W. Armstrong of the University of Alberta, Canada. The aim 
of the study was to investigate whether vericiguat, a gua-
nylate cyclase stimulator, will be well tolerated by patients 
with HFrEF and whether its use will reduce mortality and 
hospitalization rates due to cardiac decompensation. The 
study included 5050 persons who underwent randomiza-
tion and were assigned to two treatment groups (vericiguat 
or placebo) in a 1:1 ratio. The inclusion criterion was 
hospitalization due to the deterioration of heart failure 
in adults within three to six months prior to selection for 
study participation or the need for extra-hospital use of 
intravenous diuretics for the same reason within the last 
three months. Patients taking intravenous inotropic positive 
drugs, treated with long-acting nitrates, other guanylate 
cyclase stimulators (e.g. riociguat) or phosphodiesterase 
inhibitors, or left ventricular assist devices were excluded 
from the study. More than three-quarters of the random-
ized patients are male, more than half are European, the 
average ejection fraction is 28.9 ± 8.3%, the majority 
are New York Heart Association (NYHA) class II patients, 
and the average time from the diagnosis of heart failure 
expressed in years is 4.8 ± 3.4. Scheduled 18 months of 
observation (from randomization to final visit), included 
vericiguat treatment lasting an average of 480 days — the 
median of actual observation time was 10.8 months. The 
drug tested was applied orally, initially at a dose of 2.5 mg, 
which in the case of good tolerance was gradually increased 
to 10 mg. After only three months, the beneficial effects 
of adding vericiguat to standard heart failure therapy were 
noticed; this effect lasted until the end of the program. The 
results of the analyses showed that in the vericiguat group, 
compared to the placebo group, a significant (p = 0.019), 
10% reduction in the risk of a composite endpoint in the 
form of cardiovascular death or hospitalization due to 
decompensated heart failure was achieved — mainly due 
to a decrease in the second component frequency. The 
percentage of adverse events (hypotonia and fainting) 
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observation of the fate of a subgroup that was selected 
from among candidates for the ISCHEMIA trial, described 
in more detail in a report on the Scientific Sessions of 
American Heart Association 2019 [3], and which was 
composed of individuals who, despite a positive result 
of a stress test, were not diagnosed with coronary artery 
stenosis greater than 50% using imaging studies and 
were ultimately not included in the ISCHEMIA trial. As 
Dr. Harmony R. Reynolds, reporting on the CIAO study, 
said, it is a group of patients (usually females) often 
“sent on their way” by doctors who believe that non-
critical coronary artery stenosis is a guarantee of the safe 
course of ischemic heart disease. A year-long observation 
of 208 patients (of which 66% were female) included 
in the CIAO study and 1,079 patients included in the 
ISCHEMIA trial due to the presence of ≥ 50% stenosis (of 
which 26% of were female) showed that despite a similar 
baseline outcome of the stress test, the course of coro-
nary artery disease is even more worrying for the patient 
and the doctor than in the group of patients with ≥ 50% 
stenosis in coronary arteries. This is illustrated by the 
following figures: a higher percentage of patients in the 
CIAO group experienced recurrent angina pectoris once 
a week or more often than in the ISCHEMIA group within 
12 months of the initial stress test (most often a stress 
echo test) — 17% vs. 4%, and a lower percentage reported 
no coronary artery pain within the last month — 41% vs. 
62%. Interestingly, in half of the subjects, the follow-up 
stress echo test after a year showed a normal result, and 
in 45% — the result was the same as at the beginning of 
the study. In conclusion, Dr. H.R. Reynolds emphasized 
that it is important not to underestimate complaints about 
coronary artery pain, despite being aware of the lack of 
critical stenosis in these patients, as they are also pa-
tients with a significant cardiac risk, although lower than 
that of classical coronary artery disease [4, 5].
Another report concerns non-obstructive hypertrophic 
cardiomyopathy. Myokardia Inc. has proposed a new drug. 
It is a reversible inhibitor of cardiac-specific myosin called 
mavacamten and tested in MAVERICK-HCM (A phase 
2 study of mavacamten in adults with symptomatic non- 
-obstructive hypertrophic cardiomyopathy), presented 
by Dr. Carolyn Ho. This study focused on assessing the 
safety of the new molecule and its impact on biomarkers 
of high prognostic value: N-terminal pro-B-type natriuretic 
peptide (NT-proBNP) and troponin I. The percentage of 
patients with serious adverse events was lower in the 
actively treated group (10.3%) than in the placebo group 
(21.1%) — these were mainly episodes of atrial fibrilla-
tion/flutter. In 5 out of 39 actively treated patients, the 
study was discontinued due to a decrease in the left ven-
tricular ejection fraction to ≤ 45% which was defined as 
a criterion requiring discontinuation of trial participation. 
The NT-proBNP concentration decreased (p = 0.0005) 
was similar in the vericiguat and placebo group (9.1 vs. 
7.9 and 4.0 vs. 3.5). Finding a new drug for patients with 
heart failure exacerbations was considered a major suc-
cess for the sponsor Bayer and Merck as well as for the 
project sponsors the Duke Clinical Research Institute and 
Canadian VIGOUR Center [1].
Another important clinical trial was the VOYAGER PAD 
(Vascular Outcomes Study of ASA Along with Rivaroxaban 
in Endovascular or Surgical Limb Revascularizations 
for Peripheral Artery Disease), which concerned lower 
limb atherosclerosis patients after revascularization. 
6564 patients underwent randomization — in one of the 
equal-sized arms the participants received 100 mg of 
acetylsalicylic acid (ASA) and a small dose of rivaroxaban 
(2 × 2.5 mg per day), and in the other one — ASA and 
placebo. The aim of the program is to evaluate the effects 
of treatment and safety of the therapy with the addition 
of rivaroxaban to the existing pharmacological therapy 
after interventional treatment of lower limb ischemia. The 
participants were predominantly male (74%) and their 
average age was 67 years. Two-thirds were treated using 
angioplasty with stent implantation, while the rest under-
went surgical revascularization. The primary composite 
endpoint was the incidence of acute lower limb ischemia, 
the need for limb amputation, myocardial infarction, 
stroke, or death from cardiovascular causes. Treatment 
and observation lasted on average 28 months. In the ASA 
and rivaroxaban arm, compared to the arm without factor 
Xa inhibitor, a statistically significant decrease of 15% in 
the frequency of composite endpoints was noted (17.3% 
vs. 19.9% at p = 0.009). Major bleeding as defined in 
the TIMI classification or by the International Society on 
Thrombosis and Haemostasis (ISTH) was considered the 
main adverse event. When the former one was applied, the 
difference in the frequency of major bleeding between the 
arms of the study was not statistically significant (2.65% 
vs. 1.87%), while according to the ISTH classification, the 
frequency of bleeding increased in the rivaroxaban group 
by 42% (5.94% vs. 4.06%, p = 0.007). The study was sum-
marized by the main researcher of the program, Professor 
Marc P. Bonaca of the University of Colorado School of 
Medicine (USA), stating that by adding rivaroxaban to 
the existing treatment strategy after interventions in the 
peripheral arteries, the risk of acute lower limb ischemia 
incidence was significantly reduced, and the amount of 
bleeding — although greater than in the group treated 
actively — did not translate into a greater amount of ir-
reversible intracranial or fatal bleeding [2].
The results of the accompanying CIAO-ISCHEMIA 
(Changes in Ischemia and Angina over One year among 
trial screen failures with no obstructive coronary arte-
ry disease on coronary CT angiography) registry have 
become an interesting thread in the discussion follow-
ing the publication of the ISCHEMIA results. This is an 
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after 16 weeks of taking mavacamten compared to the 
placebo. Similarly, a reduction was observed for tropo-
nin I — p = 0.009. Due to the fact that the NT-proBNP 
concentration so far has been well reflected in the de-
gree of myocardial wall stress, and troponin I indicates 
myocardial damage, MAVERICK-HCM results suggest 
that mavacamten provides an innovative and promis-
ing treatment option for patients with non-obstructive 
hypertrophic cardiomyopathy [6].
In conclusion, we would like to mention that the scien-
tific session of this year’s edition of ACC/WHF 2020 was 
attended by the Team of our Department. Among the 
few Polish works included in the sessions was the pre-
sentation of the results of 4 years of cooperation with 
ANGIONICA sp. z o.o., founded by the researchers of the 
Lodz University of Technology, the creators of a unique ap-
paratus for measuring skin autofluorescence. As we have 
observed, the parameters describing autofluorescence 
induced by compounds involved in skin redox reactions 
correlate with the probability of sleep apnea both in cardiac 
patients and in healthy persons. From a practical point of 
view, the method carries the potential of a screening tool for 
respiratory distress during sleep. The report was of interest 
to congress reviewers, who qualified it for the Spotlight on 
Special Topics session: Innovation and Technology; and the 
entire study is approved for publication in one of the next 
issues of the “Cardiology Journal” [7]. 
References
1. Armstrong PW, Pieske B, Anstrom KJ, et al. VICTORIA Study Group. 
Vericiguat in patients with heart failure and reduced ejection fra-
ction. N Engl J Med. 2020; 382(20): 1883–1893, doi: 10.1056/ 
/NEJMoa1915928, indexed in Pubmed: 32222134.
2. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in pe-
ripheral artery disease after revascularization. N Engl J Med. 2020; 
382(21): 1994–2004, doi: 10.1056/NEJMoa2000052, indexed in 
Pubmed: 32222135.
3. Rechcinski T, Kasprzak J. Nie tylko ISCHEMIA. Sprawozdanie z Ameri-
can Heart Association’s Scientific Sessions 2019, Filadelfia 16–18 li-
stopada 2019 roku. Folia Cardiol. 2020; 15(1): 84–87, doi: 10.5603/ 
/fc.2020.0011.
4. Reynolds HR, Shaw L, Min J, et al. Coronary anatomy, ischemia and an-
gina: associations at baseline in the ISCHEMIA trial. J Am Coll Cardiol. 
2020; 75(11 Suppl 1): 21, doi: 10.1016/s0735-1097(20)30648-3.
5. Reynolds HR, Shaw L, Chaitman B, et al. Sex differences in stress test 
and CCTA findings and symptoms in the randomized ISCHEMIA trial. 
J Am Coll Cardiol. 2020; 75(11 Suppl 2): 30, doi: 10.1016/s0735-
1097(20)30657-4.
6. Ho CY, Mealiffe M, Bach R, et al. Evaluation of mavacamten in 
symptomatic patients with nonobstructive hypertrophic cardiomyo-
pathy. J Am Coll Cardiol. 2020; 75(21): 2649–2660, doi: 10.1016/ 
/j.jacc.2020.03.064, indexed in Pubmed: 32466879.
7. Rechciński T, Cieślik-Guerra U, Siedlecki P, et al. Flow-mediated skin 
fluorescence: a novel method for the estimation of sleep apnea 
risk in healthy persons and cardiac patients. Cardiol J. 2020 [Epub 
ahead of print], doi: 10.5603/CJ.a2020.0139, indexed in Pubmed: 
33140392.
